Telix Pharmaceuticals (TLX) Stock Price, News & Analysis

Company Overview

Telix Pharmaceuticals Limited is a biopharmaceutical company focused on developing and commercializing radiopharmaceuticals for the diagnosis and treatment of cancer and other serious diseases. Its products use targeted molecules to deliver radioactive isotopes to specific tissues, supporting precision imaging and therapeutic applications.

The company’s commercial portfolio includes Illuccix, a gallium-68 radiolabeled prostate-specific membrane antigen (PSMA) imaging agent used with PET scans to help detect and manage prostate cancer. Telix also markets Locametz, a diagnostic kit used to prepare gallium-68 gozetotide for PSMA PET imaging. In addition, Telix is advancing investigational radiopharmaceutical therapies and diagnostic products targeting cancers including prostate, kidney, and brain tumors.

Founded in 2015 and headquartered in Melbourne, Australia, Telix serves international markets through operations and commercial activities spanning the United States, Europe, Australia, and other regions. The company was co-founded by Christian Behrenbruch, who serves as managing director and group chief executive officer.

Key Stats

• Today's Range: $11.20 to $11.75
• 50-Day Range: $9.89 to $12.42
• 52-Week Range: $6.28 to $12.48
• Volume: 414,798 shs
• Average Volume: 184,032 shs
• Market Capitalization: $3.84 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $20.40
• Consensus Rating: Moderate Buy

Telix Pharmaceuticals Stock Analysis - MarketRank™

Telix Pharmaceuticals scored higher than 67% of companies evaluated by MarketBeat, and ranked 302nd out of 904 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Telix Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on 1 strong buy rating, 4 buy ratings, 2 hold ratings, and no sell ratings.

Upside Potential

Telix Pharmaceuticals has a consensus price target of $20.40, representing about 80.7% upside from its current price of $11.29.

Amount of Analyst Coverage

Telix Pharmaceuticals has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: -14.29%

Earnings Growth

Earnings for Telix Pharmaceuticals are expected to decrease by -14.29% in the coming year, from $0.07 to $0.06 per share.

Price to Book Value per Share Ratio

Telix Pharmaceuticals has a P/B Ratio of 9.18. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.08% of the float of Telix Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Telix Pharmaceuticals has a short interest ratio ("days to cover") of 1.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Telix Pharmaceuticals has recently increased by 8.18%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Telix Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Telix Pharmaceuticals does not have a long track record of dividend growth.

News and Social Media

• Score: 2.4 / 5
• News Sentiment: 0.89

News Sentiment

Telix Pharmaceuticals has a news sentiment score of 0.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Telix Pharmaceuticals this week, compared to 9 articles on an average week.

Search Interest

3 people have searched for TLX on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.

Company Ownership

• Score: N/A
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Telix Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Institutions

Telix Pharmaceuticals has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 2/20/2026
• Today: 9/12/2026
• Morgan Stanley 24th Annual Global Healthcare Conference: 9/14/2026
• H.C. Wainwright 28th Annual Global Investment Conference: 9/15/2026
• Investor Day 2026: 11/03/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:TLX
• Previous Symbol: NASDAQ:TLX
• CIK: 2007191
• Web: www.telixpharma.com
• Phone: 61-3-9093-3855
• Fax: N/A
• Employees: 1,184
• Year Founded: 2015

Price Target and Rating

• Average Price Target for Telix Pharmaceuticals: $20.40
• High Price Target: $22.00
• Low Price Target: $18.00
• Potential Upside/Downside: +80.7%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.86
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: 1.16
• Current Ratio: 2.01
• Quick Ratio: 1.85

Sales & Book Value

• Annual Sales: $803.79 million
• Price / Sales: 4.77
• Cash Flow: $0.04 per share
• Price / Cash Flow: 267.77
• Book Value: $1.23 per share
• Price / Book: 9.18

Miscellaneous

• Outstanding Shares: 339,780,000
• Free Float: N/A
• Market Cap: $3.84 billion
• Optionable: N/A
• Beta: -0.17